We also participated in several hair care product launches by some of our large multinational customers and several body lotion and spray products that are equipped with our dispensing systems that were launched in Russia, Poland and Thailand. Now looking at our pharma segment, strong demand for our nasal delivery devices from the prescription drug market was partially offset by weaker sales to the consumer healthcare market.We’re particularly pleased that we began shipping from our new facility in Mumbai, India during the quarter as anticipated. Also it was an exciting quarter in terms of approvals of new drugs that are equipped with our delivery systems. There were a couple of approvals that happened in the quarter, that did not impact our results. But are important nonetheless as they relate to the debut of our patented dose indicator called Landmark.
AptarGroup's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts